© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
The investigational therapy is being evaluated in a phase 2 study for the reduction in risk of major thrombotic cardiovascular events in patients with ESRD on hemodialysis.
The
Following is a summary of current health news briefs.
Britain approves Novavax COVID shot for 12-17 year-olds
Britain's medicines regulator on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years. The mRNA vaccines made by Moderna as well as the part
Tiny alginate bead implants invented in the laboratory of Rice University bioengineer Omid Veiseh can be loaded with cells that produce cytokine, proteins that play a major role in immune response. A new study found a treatment combining the implants and checkpoint inhibitor drugs eradicated a
As the global economy mends, the 2021 growth of High Pressure Contrast Injector will have significant change from previous year. According to our (LP Information) latest study, the global High Pressure Contrast Injector market size is USD million in 2022 from USD million in 2021,
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
Terry Tang, Associated Press
Get local news, offers & more...
Playhouse on the Square, in partnership with An Anonymous Company and super sponsor Dr. Thomas Ratliff, is excited to present the Regional Premiere of PASS OVER by Antoinette Nwandu. Running September 16 - October 19, 2022 at The Circuit Playhouse, Ov
Doug Lawrence, CEO, Hygieia (Photo: Business Wire)
Doug Lawrence, CEO, Hygieia (Photo: Business Wire)
LIVONIA, Mich.--(BUSINESS WIRE )--Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading ope
LIVONIA – Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.
Lawrence brings three decades of m
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued sup